-
Recent Posts
Recent Comments
Archives
- October 2012
- December 2011
- November 2011
- September 2011
- March 2011
- December 2010
- November 2010
- September 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- November 2009
- October 2009
- September 2009
- July 2009
- June 2009
- February 2009
- January 2009
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- February 2007
- December 2006
- November 2006
- October 2006
- August 2006
- April 2006
- March 2006
- December 2005
- November 2005
- July 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
Categories
Meta
Monthly Archives: December 2007
Varenicline (brand name Champix) European wide review
EMEA have issued a warning about suicidal ideation and suicide attempts associated with varenicline [PDF]: The European Medicines Agency (EMEA) has concluded that updated warnings to doctors and patients are needed to increase awareness of cases of suicidal ideation and … Continue reading
Posted in EMEA
Comments Off
Withdrawal of lumiracoxib
EMEA have withdrawn lumiracoxib from the European market due to its effects on the liver [PDF]: The liver safety of lumiracoxib has been monitored continuously since its launch in 2005. In August 2007, the product information was updated with contraindications … Continue reading
Posted in EMEA
Comments Off
Carbamazepine: Dangerous & fatal skin reactions
Carbamazepine’s propensity to skin rashes is well known, with 5-20% of patients developing skin rashes which can lead to drug withdrawal. It is also associated relatively rarely with more serious skin reactions such as exfoliative dermititis, Stevens Johnson syndrome (SJS) … Continue reading
Posted in FDA
Comments Off
Reducing Paediatric medication errors
The use of medicines in children is a dangerous activity. Physical and physiological differences between children and adults, and the comparative lack of data for drug use in children makes decisions about dosing complex. Often specifically licensed childrens preparations are … Continue reading
Posted in Patient Safety
Comments Off
FDA review of omeprazole and esomeprazole
The FDA has completed its review of the safety of omeprazole and esomeprazole, in the wake of two studies that appeared to show higher rates of cardiac events in those treated with the proton pump inhibitors (PPIs). Both of these … Continue reading
Posted in FDA
Comments Off
Recent Research Findings
The following are three posters this unit recently presented at ISOP 2007 in October of this year: Cox AR, Anton C, Marriott JF, Ferner RE. The paradox of low prescribers who are high reporters: correlates of spontaneous reporting of adverse … Continue reading
Posted in Our research
Comments Off
Challenges for the FDA:The Future of Drug Safety
The National Academies Press has published Challenges for the FDA:The Future of Drug Safety, Workshop Summary, which is the result of a one-day symposium in March of this year. The text is free online.
Posted in FDA
Comments Off
MHRA Annual Conference 2008
The MHRA Annual Conference will be held in Birmingham this year.
Salmeterol in children
The NPC draw attention to a FDA document on the safety of salmeterol in children, and provide extensive links on material to help prescribers.
Posted in FDA
Comments Off
The safe dispensing of medicines
The NPSA have issued two booklets about the safe dispensing of medicines. 1. A guide to the design of the dispensing environment. 2. A guide to the design of dispensed medicines. A BMJ news report summerises the key points as: … Continue reading
Posted in Patient Safety
Comments Off